2444-054X

S2444-054X2025000700001

10.24875/ciru.m25000069

México

00 00 2025

93 1 35

Global cancer statistics

2021 71 3 3

209-49

2015 34 4 4

323-33

2020 126 10 10

2225-49

2022

2001

2010 182

E839-842

2022 46

2008 49 6 6

688-93

2022 21 3 3

209-28

2022 399 10333 10333

1412-28

International agency for research on cancer

2021 161 2 2

573-80

2016 215 5 5

598.e1-8

2020 12 10 10

9825-39

2015 73 7 7

409-25

2014 111 7 7

1432-9

2016 91

25-35

2018 105 9 9

1098-106

2020 72 6 6

959-67

2022 67 3 3

109-20

2015 7 7 7

5697-711

2017 9 11 11

1223

2011 55 6 6

931-40

2015 112 11 11

1816-21

2017 26 4 4

336-45

2022 306 2 2

407-21

2014 34 5 5

1477-84

2021 147 7 7

2035-45

2012 40 6 6

621-9

2012 33 1 1

60-1

2023 61 4 4

609-25

1997

Expert Panel on GYN and OB Imaging

2020 17 11S 11S

S472-86

2014 34 4 4

1082-98

2023 43 8 8

2021 58 3 3

469-75

2018 13 2 2

143-63

2021 43 1 1

41-5

2023 21 2 2

181-209

College of American Patologists 2023

2023 34 5 5

2021 29

2022 5 12 12

WHO Classification of Tumours Editorial Board 2020

2023 34 2 2

2020 38 29 29

3388-97

2015 2015

219012

2020 25 9^s12 9^s12 12

2407

2013 40 4 4

167-75

2012 21 2 2

151-61

2016 43 5 5

543-7

2019 155

508-14

2022 23 3 3

1563

2021 19 10 10

1122-32

2022 61

314-21

2022 31

369-76

2022 14

3406

2019 36 1 1

37-42

2014 134 2 2

319-25

2017 70

121-8

ANECS Group

2017 147 2 2

381-7

National Comprehensive Cancer Network

2024

2014 146

1208-1211.e5

2018 67

1306-16

2021

2019 21 10 10

2167-80

ESMO Guidelines Committee

2022 33 9 9

860-77

2023 19 3 3

701-7

2019 21 10 10

2390-400

2014 132 2 2

434-7

2017 64 5 5

836-43

2022 32 5 5

646-55

2023 30 9 9

7904-19

ASTEC/EN.5 Study Group

2009 373 9658 9658

137-46

2017 18 3 3

384-92

2017 317 12 12

1224-33

2000 78 2 2

85-91

2021 100 14 14

2023 42 1 1

24-32

2018 10 3 3

2022 81

104470

2015 25 5 5

837-42

2022 12 11 11

2834

2018 298 3 3

505-10

2017 8 28 28

46601-10

2019 153 3 3

676-83

2023 33 6 6

853-9

2012 207 2 2

94-100

2021 6 6 6

CD013021

2023 171

121-8

2022 481 3 3

421-32

2021 225 4 4

367.e1-367.e39

2019 221 1 1

39.e1-39.e14

2022 22 1 1

703

2019 9 4 4

248-56

2010 118 1 1

14-8

2022 43

101811

100

2019 154 1 1

38-44

101

2021 13 22 22

5848

102

2021 31 1 1

12-39

103

2022 29 4 4

1068-85

104

2010 375 9717 9717

816-23

105

PORTEC study group

2018 19 3 3

295-309

106

2018 29 1 1

107

2018

108

PORTEC Study Group

2011 81 4 4

e631-8

109

2004 92 3 3

744-51

110

2015 51 13 13

1742-50

111

PORTEC Study Group

2023 41 27 27

4369-80

112

2015 33 26 26

2908-13

113

2004 92 3 3

744-51

114

2021 33 9 9

560-6

115

2013 497 7447 7447

67-73

116

2019 37 21 21

1810-8

117

2019 380 24 24

2317-26

118

2000 355

1404-11

119

2013 86

83-90

120

2018 119

1067-74

121

2017 146

240-6

122

2019 154

475-9

123

2020 157

329-34

124

2022 21 2 2

177-85

125

2012 84

e23-28

126

2018 36

2538-44

127

2009 27 21 21

3547-56

128

2024 50 3 3

485-93

129

2021 7 11 11

130

2021 398 10314 10314

1894-904

131

2021 304 3 3

773-82

132

2020 33 1 1

118-27

133

RUBY Investigators

2023 388 23 23

2145-58

134

Instituto Mexicano del Seguro Social

135

2022 40 28 28

3289-300

136

2012 2012 8 8

CD003915

137

2023 11 6 6

e006624-4

138

2022 40 7 7

752-61

139

RUBY Investigators

2023 388 23 23

2145-58

140

2023 16

359-69

141

1989 32

1-3

142

2010 2010 12 12

CD007926

143

2020 60 4 4

754-64

144

2018 78 11 11

1089-109

145

2009 169 5 5

480

146

2017 217 4 4

434.e1-434.e10

147

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 2023

148

2017 35 1 1

96-112

149

2022 82 2 2

181-205

150

2023 15

17588359231157645

151

2020 139

149-68

152

2019 25 7 7

2155-65

153

2023

154

Taiwan Association of Gynecology Systematic Review Group

2016 55 4 4

472-9

155

2022 82 12 12

1337-67

156

2021 155 S1 S1

45-60

157

2022 279

94-101

158

2022 167 2 2

373-89

159

2021 13 22 22

5808

160

2019 300 5 5

1167-75

161

2017 146 2 2

254-62

162

2007 97 9 9

1194-9

163

2007 19 4 4

347-52

164

2013 24 4 4

1099-104

165

2017 146 3 3

531-7

166

2022

167

2019

283-8

168

2019 29 4 4

691-8

169

2013 122 1 1

57-61

170

ESMO Guidelines Committee

2021 32 11 11

1348-65

171

2022 23 8 8

1044-54

172

2007 106

82-8

173

2021 30

57-67

174

2004 127

1107-12

175

2011 8 6 6

378-82

176

2015 25 9 9

1645-51

177

2005 97 2 2

624-37

178

2012 286 6 6

1529-35

179

2017 18 10 10

1397-410

180

2016 12 6 6

4739-43

181

2023 24 12 12

1683-702

182

2016 34 8 8

786-93

183

2013 13

385

184

2011 29 18 18

2528-33

185

EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group

2012 379 9829 9829

1879-86

186

2003 98 9 9

1942-6